There are a large number of pharmaceutical products in the market containing heterocyclic compounds. Heterocyclic compounds are explored in the field of therapeutics due to their unique physicochemical and pharmacological properties. A large number of heterocyclic compounds existing in the pharmaceutical market have marked anticancer activity and many of them are under research investigations to treat different types of cancers. Anticancer heterocyclic compounds show many shortcomings such as other anticancer agents in bioavailability and site-specific drug delivery resulting in toxicity and decreased patient compliance. These shortcomings can be eliminated by applying the principles of nanotechnology. The present review discloses the biochemical mechanism of action, different biological targets, intrinsic shortcomings, and structure-activity relationships of anticancer heterocyclic compounds. Furthermore, the role of different nanocarrier systems in selective biological targeting and alteration of pharmacokinetic and pharmacodynamic characteristics of anticancer heterocyclic compounds will be discussed in detail.
{"title":"Exploring the Therapeutic Potential of Anticancer Heterocyclic Compounds: Role in Nanoscale Pharmacotherapy.","authors":"Lalit Kumar, Shivani Verma, Kajal Joshi, Sumit Sharma","doi":"10.1615/CritRevTherDrugCarrierSyst.2022039548","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022039548","url":null,"abstract":"<p><p>There are a large number of pharmaceutical products in the market containing heterocyclic compounds. Heterocyclic compounds are explored in the field of therapeutics due to their unique physicochemical and pharmacological properties. A large number of heterocyclic compounds existing in the pharmaceutical market have marked anticancer activity and many of them are under research investigations to treat different types of cancers. Anticancer heterocyclic compounds show many shortcomings such as other anticancer agents in bioavailability and site-specific drug delivery resulting in toxicity and decreased patient compliance. These shortcomings can be eliminated by applying the principles of nanotechnology. The present review discloses the biochemical mechanism of action, different biological targets, intrinsic shortcomings, and structure-activity relationships of anticancer heterocyclic compounds. Furthermore, the role of different nanocarrier systems in selective biological targeting and alteration of pharmacokinetic and pharmacodynamic characteristics of anticancer heterocyclic compounds will be discussed in detail.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 3","pages":"47-94"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Rheumatoid Arthritis (RA) is classified as a chronic inflammatory autoimmune disorder that is associated with a varied range of immunological changes, synovial hyperplasia, cartilage destructions, as well as bone erosion. Even though many conventional drugs are suggested by a medical practitioner such as DMARDs, NSAIDs, glucocorticoids, etc. to treat RA, but, they have allied with various side effects. Therefore, this study tries to compile the most recent research on how plant-based compounds/nano-formulations can combat RA with minimal or no adverse effects. Methods: Databases including Google, Science Direct, Google Scholar, Web of Science, PubMed, Scopus, and Research Gate have been looked through for potentially existing research with the goal of discovering the latest progress on multiple viewpoints of phyto-compounds over RA. Results: In order to decrease the generation of pro-inflammatory cytokines, many phyto-compounds have been reported that regulate cell cycle arrest, FLS proliferation, autophagy, apoptosis, and numerous signaling pathways. Also, the therapeutic difficulties and clinical usefulness of nano-delivery systems are investigated. Conclusions: A tailored approach for treating inflamed tissue may possibly improve the therapeutic efficacy of the drug while reducing its systemic adverse effects. Additionally, the growing herbal revolution has led to the invention of new methods for delivering poorly soluble herbal bioactives and plant extracts to improve their efficacy at targeted inflamed synovial sites.
目的:类风湿关节炎(RA)被归类为一种慢性炎症性自身免疫性疾病,与各种免疫变化、滑膜增生、软骨破坏以及骨侵蚀有关。尽管医生建议许多常规药物如DMARDs、非甾体抗炎药、糖皮质激素等治疗类风湿性关节炎,但它们都有各种副作用。因此,本研究试图汇编关于植物基化合物/纳米制剂如何在最小或没有副作用的情况下对抗类风湿性关节炎的最新研究。方法:通过Google、Science Direct、Google Scholar、Web of Science、PubMed、Scopus、Research Gate等数据库查找潜在的现有研究,从多个角度发现植物化合物治疗类风湿性关节炎的最新进展。结果:为了减少促炎细胞因子的产生,许多植物化合物被报道可以调节细胞周期阻滞、FLS增殖、自噬、凋亡和许多信号通路。此外,研究了纳米递送系统的治疗困难和临床用途。结论:治疗炎症组织的量身定制方法可能提高药物的治疗效果,同时减少其全身不良反应。此外,不断发展的草药革命已经导致了新方法的发明,用于输送难溶性草药生物活性物质和植物提取物,以提高其在靶向炎症滑膜部位的功效。
{"title":"Plant-based approaches for rheumatoid arthritis regulation: Mechanistic insights on pathogenesis, molecular pathways and delivery systems","authors":"Anita Bhoi, Shradha Devi Dwivedi, Deependra Singh, Sahu Keshavkant, Manju Singh","doi":"10.1615/critrevtherdrugcarriersyst.2023048324","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2023048324","url":null,"abstract":"Purpose: Rheumatoid Arthritis (RA) is classified as a chronic inflammatory autoimmune disorder that is associated with a varied range of immunological changes, synovial hyperplasia, cartilage destructions, as well as bone erosion. Even though many conventional drugs are suggested by a medical practitioner such as DMARDs, NSAIDs, glucocorticoids, etc. to treat RA, but, they have allied with various side effects. Therefore, this study tries to compile the most recent research on how plant-based compounds/nano-formulations can combat RA with minimal or no adverse effects. Methods: Databases including Google, Science Direct, Google Scholar, Web of Science, PubMed, Scopus, and Research Gate have been looked through for potentially existing research with the goal of discovering the latest progress on multiple viewpoints of phyto-compounds over RA. Results: In order to decrease the generation of pro-inflammatory cytokines, many phyto-compounds have been reported that regulate cell cycle arrest, FLS proliferation, autophagy, apoptosis, and numerous signaling pathways. Also, the therapeutic difficulties and clinical usefulness of nano-delivery systems are investigated. Conclusions: A tailored approach for treating inflamed tissue may possibly improve the therapeutic efficacy of the drug while reducing its systemic adverse effects. Additionally, the growing herbal revolution has led to the invention of new methods for delivering poorly soluble herbal bioactives and plant extracts to improve their efficacy at targeted inflamed synovial sites.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135495872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2022044495
Sourabh Jadhav, Ankaj Kumar, Arvind Gulbake
The exosome is a naturally derived nanostructured lipid vesicle that ranges from 40-100 nm in size and is utilized to transport drugs, and biological macromolecules, including therapeutic RNA and proteins. It is a membrane vesicle actively released by cells to transport cellular components with a purpose for biological events. The conventional isolation technique has several drawbacks, including low integrity, low purity, long processing time, and sample preparation. Therefore, microfluidic technologies are more widely accepted for the isolation of pure exosomes, but due to cost and expertise requirements, this technology is also facing challenges. The bioconjugation of small and macro-molecules to the surface of exosomes is a very interesting and emerging approach for achieving the specific target, therapeutic purpose, in vivo imaging, and many more. Although emerging strategies resolve a few challenges, exosomes are still unexplored complex nano-vesicles with excellent properties. This review has briefly elaborated on contemporary isolation techniques and loading approaches. We have also discussed the surface-modified exosomes by different conjugation methods and their applications as targeted drug delivery vesicles. The challenges associated with the exosomes, patents, and clinical investigations are the main highlight of this review.
{"title":"Exosomes: Recent Advances and Challenges as Targeted Therapeutic Delivery Vesicles.","authors":"Sourabh Jadhav, Ankaj Kumar, Arvind Gulbake","doi":"10.1615/CritRevTherDrugCarrierSyst.2022044495","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022044495","url":null,"abstract":"<p><p>The exosome is a naturally derived nanostructured lipid vesicle that ranges from 40-100 nm in size and is utilized to transport drugs, and biological macromolecules, including therapeutic RNA and proteins. It is a membrane vesicle actively released by cells to transport cellular components with a purpose for biological events. The conventional isolation technique has several drawbacks, including low integrity, low purity, long processing time, and sample preparation. Therefore, microfluidic technologies are more widely accepted for the isolation of pure exosomes, but due to cost and expertise requirements, this technology is also facing challenges. The bioconjugation of small and macro-molecules to the surface of exosomes is a very interesting and emerging approach for achieving the specific target, therapeutic purpose, in vivo imaging, and many more. Although emerging strategies resolve a few challenges, exosomes are still unexplored complex nano-vesicles with excellent properties. This review has briefly elaborated on contemporary isolation techniques and loading approaches. We have also discussed the surface-modified exosomes by different conjugation methods and their applications as targeted drug delivery vesicles. The challenges associated with the exosomes, patents, and clinical investigations are the main highlight of this review.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 4","pages":"101-133"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2023045480
Neeraj Mittal, Gajanand Sharma, Om Parkash Katare, Sanjay Kumar Bhadada
In the field of pharmaceutical biotechnology and formulation development, various protein and peptide-based drugs have been used for therapeutic and clinical implications. These are mainly given via parenteral routes like intravenous, subcutaneous or intramuscular delivery. Teriparatide, also known as PTH 1-34, is a U.S. Food & Drug Administartion-approved anabolic drug to treat osteoporosis is currently available in market only as subcutaneous injection. The quest for elimination of needle in case of given peptidal delivery to replace it with alternative routes like nasal, buccal, transdermal and pulmonary pathways has driven meticulous drug research. The pharmaceutical scientists are working on innovation and approaches involving new materials and methods to develop the formulations for protein and peptides by noninvasive routes. Lately, various approaches have been carried out which involve many strategies and technologies to deliver teriparatide via alternative routes. But, physicochemical instability, proteolytic degradation, low bioavailability, etc. are some obstacles to develop suitable delivery system for teriparatide. This review intends to gather the overall developments in delivery systems specific to teriparatide which meant for better convenience and avoids vulnerability of multiple subcutaneous injections. In addition, the article emphasizes on the successes to develop noninvasive technologies and devices, and new milestones for teriparatide delivery.
{"title":"A Narrative Review on Non-Invasive Drug Delivery of Teriparatide: A Ray of Hope.","authors":"Neeraj Mittal, Gajanand Sharma, Om Parkash Katare, Sanjay Kumar Bhadada","doi":"10.1615/CritRevTherDrugCarrierSyst.2023045480","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023045480","url":null,"abstract":"<p><p>In the field of pharmaceutical biotechnology and formulation development, various protein and peptide-based drugs have been used for therapeutic and clinical implications. These are mainly given via parenteral routes like intravenous, subcutaneous or intramuscular delivery. Teriparatide, also known as PTH 1-34, is a U.S. Food & Drug Administartion-approved anabolic drug to treat osteoporosis is currently available in market only as subcutaneous injection. The quest for elimination of needle in case of given peptidal delivery to replace it with alternative routes like nasal, buccal, transdermal and pulmonary pathways has driven meticulous drug research. The pharmaceutical scientists are working on innovation and approaches involving new materials and methods to develop the formulations for protein and peptides by noninvasive routes. Lately, various approaches have been carried out which involve many strategies and technologies to deliver teriparatide via alternative routes. But, physicochemical instability, proteolytic degradation, low bioavailability, etc. are some obstacles to develop suitable delivery system for teriparatide. This review intends to gather the overall developments in delivery systems specific to teriparatide which meant for better convenience and avoids vulnerability of multiple subcutaneous injections. In addition, the article emphasizes on the successes to develop noninvasive technologies and devices, and new milestones for teriparatide delivery.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"117-140"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cyclosporine (CsA) stays the most intangible molecule holding a good history for treating several ophthalmic conditions and it even attributes to multiple off-label uses. Topical delivery of CsA is the most preferred route but owing to the molecule's physicochemical properties such as poor aqueous solubility and high molecular weight as well as its encounter with multiple barriers of eye causes hindrance for proper delivery of the molecule to the site of action. However, Restasis®, Cequa®, and Verkazia® are the marketed formulations that have been approved by U.S. Food and Drug Administration, whereas Cyclokat® and Ikervis® by the European Medicines Agency. Although these medications are in use, they are associated with severe discomfort and poor patient compliance. This review gives an overview regarding current formulations available in the market, the products in pipeline and the recent advances undertaken for improving ocular delivery of CsA for various ophthalmic indications.
{"title":"Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems.","authors":"Garima Rawat, Shital Kolhe, Dhwani Rana, Sagar Salave, Derajram Benival","doi":"10.1615/CritRevTherDrugCarrierSyst.2022043085","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022043085","url":null,"abstract":"<p><p>Cyclosporine (CsA) stays the most intangible molecule holding a good history for treating several ophthalmic conditions and it even attributes to multiple off-label uses. Topical delivery of CsA is the most preferred route but owing to the molecule's physicochemical properties such as poor aqueous solubility and high molecular weight as well as its encounter with multiple barriers of eye causes hindrance for proper delivery of the molecule to the site of action. However, Restasis®, Cequa®, and Verkazia® are the marketed formulations that have been approved by U.S. Food and Drug Administration, whereas Cyclokat® and Ikervis® by the European Medicines Agency. Although these medications are in use, they are associated with severe discomfort and poor patient compliance. This review gives an overview regarding current formulations available in the market, the products in pipeline and the recent advances undertaken for improving ocular delivery of CsA for various ophthalmic indications.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 5","pages":"1-45"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2023042400
Ifrah Anwar, Usman Ali Ashfaq
The liver is one of the crucial organs of the body that performs hundreds of chemical reactions needed by the body to survive. It is also the largest gland of the body. The liver has multiple functions, including the synthesis of chemicals, metabolism of nutrients, and removal of toxins. It also acts as a storage unit. The liver has a unique ability to regenerate itself, but it can lead to permanent damage if the injury is beyond recovery. The only possible treatment of severe liver damage is liver transplant which is a costly procedure and has several other drawbacks. Therefore, attention has been shifted towards the use of stem cells that have shown the ability to differentiate into hepatocytes. Among the numerous kinds of stem cells (SCs), the mesenchymal stem cells (MSCs) are the most famous. Various studies suggest that an MSC transplant can repair liver function, improve the signs and symptoms, and increase the chances of survival. This review discusses the impact of combining stem cell therapy with nanotechnology. By integrating stem cell science and nanotechnology, the information about stem cell differentiation and regulation will increase, resulting in a better comprehension of stem cell-based treatment strategies. The augmentation of SCs with nanoparticles has been shown to boost the effect of stem cell-based therapy. Also, the function of green nanoparticles in liver therapies is discussed.
{"title":"Impact of Nanotechnology on Differentiation and Augmentation of Stem Cells for Liver Therapy.","authors":"Ifrah Anwar, Usman Ali Ashfaq","doi":"10.1615/CritRevTherDrugCarrierSyst.2023042400","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023042400","url":null,"abstract":"<p><p>The liver is one of the crucial organs of the body that performs hundreds of chemical reactions needed by the body to survive. It is also the largest gland of the body. The liver has multiple functions, including the synthesis of chemicals, metabolism of nutrients, and removal of toxins. It also acts as a storage unit. The liver has a unique ability to regenerate itself, but it can lead to permanent damage if the injury is beyond recovery. The only possible treatment of severe liver damage is liver transplant which is a costly procedure and has several other drawbacks. Therefore, attention has been shifted towards the use of stem cells that have shown the ability to differentiate into hepatocytes. Among the numerous kinds of stem cells (SCs), the mesenchymal stem cells (MSCs) are the most famous. Various studies suggest that an MSC transplant can repair liver function, improve the signs and symptoms, and increase the chances of survival. This review discusses the impact of combining stem cell therapy with nanotechnology. By integrating stem cell science and nanotechnology, the information about stem cell differentiation and regulation will increase, resulting in a better comprehension of stem cell-based treatment strategies. The augmentation of SCs with nanoparticles has been shown to boost the effect of stem cell-based therapy. Also, the function of green nanoparticles in liver therapies is discussed.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"89-116"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2022041829
Tahmidul Islam Aquib
Over the past decade, lignin-based nanomaterials have astonishingly gained tremendous popularity among researchers worldwide for utilization in various high-value added fields. However, the copiousness of published articles suggests that lignin-based nanomaterials are currently being given the most priority as drug delivery vehicles or drug carriers. A large number of reports have been published during the past decade reporting successful application of lignin nanoparticles as drug carrier, not only for drugs administered in human but also for drugs used in plants such as pesticides, fungicides, etc. In this review, all of these reports have been discussed in an elaborate fashion so as to present all the available information pertaining to the application of lignin-based nanomaterials in drug delivery in a comprehensive manner.
{"title":"Lignin-Based Nanomaterials as Drug Delivery Vehicles: A Review.","authors":"Tahmidul Islam Aquib","doi":"10.1615/CritRevTherDrugCarrierSyst.2022041829","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022041829","url":null,"abstract":"<p><p>Over the past decade, lignin-based nanomaterials have astonishingly gained tremendous popularity among researchers worldwide for utilization in various high-value added fields. However, the copiousness of published articles suggests that lignin-based nanomaterials are currently being given the most priority as drug delivery vehicles or drug carriers. A large number of reports have been published during the past decade reporting successful application of lignin nanoparticles as drug carrier, not only for drugs administered in human but also for drugs used in plants such as pesticides, fungicides, etc. In this review, all of these reports have been discussed in an elaborate fashion so as to present all the available information pertaining to the application of lignin-based nanomaterials in drug delivery in a comprehensive manner.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 4","pages":"1-67"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2022041853
Vasanti Suvarna, Niserga Sawant, Namita Desai
Unmodified nanocarriers used in the chemotherapy of cancers and various infectious diseases exhibit prolonged blood circulation time, prevent enzymatic degradation and increase chemical stability of encapsulated therapeutics. However, off-target effect and lack of specificity associated with unmodified nanoparticles (NPs) limit their applications in the health care system. Mannose (Man) receptors with significant overexpression on antigen-presenting cells and macrophages are among the most admired targets for cancer and anti-infective therapeutics. Therefore, development of Man functionalized nanocarriers targeting Man receptors, for target specific drug delivery in the chemotherapy have been extensively studied. Present review expounds diverse Man-conjugated NPs with their potential for targeted drug delivery, improved biodistribution profiles and localization. Additionally, the review gives detailed account of the interactions of mannosylated NPs with various biological systems and their characterization not discussed in earlier published reports is discussed.
{"title":"A Review on Recent Advances in Mannose-Functionalized Targeted Nanocarrier Delivery Systems in Cancer and Infective Therapeutics.","authors":"Vasanti Suvarna, Niserga Sawant, Namita Desai","doi":"10.1615/CritRevTherDrugCarrierSyst.2022041853","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022041853","url":null,"abstract":"<p><p>Unmodified nanocarriers used in the chemotherapy of cancers and various infectious diseases exhibit prolonged blood circulation time, prevent enzymatic degradation and increase chemical stability of encapsulated therapeutics. However, off-target effect and lack of specificity associated with unmodified nanoparticles (NPs) limit their applications in the health care system. Mannose (Man) receptors with significant overexpression on antigen-presenting cells and macrophages are among the most admired targets for cancer and anti-infective therapeutics. Therefore, development of Man functionalized nanocarriers targeting Man receptors, for target specific drug delivery in the chemotherapy have been extensively studied. Present review expounds diverse Man-conjugated NPs with their potential for targeted drug delivery, improved biodistribution profiles and localization. Additionally, the review gives detailed account of the interactions of mannosylated NPs with various biological systems and their characterization not discussed in earlier published reports is discussed.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 2","pages":"43-82"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2023042979
Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.
{"title":"Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis.","authors":"Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu","doi":"10.1615/CritRevTherDrugCarrierSyst.2023042979","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023042979","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"1-87"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10010645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2022042252
Minkal Tuteja, Kalpana Nagpal
This work is an effort to first introduce plant-based gums and discussing their drug delivery applications. The composition of these plant gums and their major characteristics, which make them suitable as pharmaceutical excipients are also described in detail. The various modifications methods such as physical and chemical modifications of gums and polysaccharides have been discussed along with their applications in different fields. Consequently, plant-based gums modification such as etherification and grafting is attracting much scientific attention to satisfy industrial demand. The evaluation tests to characterize gum-based drug delivery systems have been summarized. The release behavior of drug from plant-gum-based drug delivery is being discussed. Thus, this review is an attempt to critically summarize different aspect of plant-gum-based polysaccharides to be utilized in drug delivery systems having potential industrial applications.
{"title":"Recent Advances and Prospects for Plant Gum-Based Drug Delivery Systems: A Comprehensive Review.","authors":"Minkal Tuteja, Kalpana Nagpal","doi":"10.1615/CritRevTherDrugCarrierSyst.2022042252","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022042252","url":null,"abstract":"<p><p>This work is an effort to first introduce plant-based gums and discussing their drug delivery applications. The composition of these plant gums and their major characteristics, which make them suitable as pharmaceutical excipients are also described in detail. The various modifications methods such as physical and chemical modifications of gums and polysaccharides have been discussed along with their applications in different fields. Consequently, plant-based gums modification such as etherification and grafting is attracting much scientific attention to satisfy industrial demand. The evaluation tests to characterize gum-based drug delivery systems have been summarized. The release behavior of drug from plant-gum-based drug delivery is being discussed. Thus, this review is an attempt to critically summarize different aspect of plant-gum-based polysaccharides to be utilized in drug delivery systems having potential industrial applications.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 2","pages":"83-124"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}